VONVENDI
TM
[von Willebrand factor (Recombinant)]
IS IN YOUR CORNER
THE FIRST AND ONLY RECOMBINANT
VON WILLEBRAND FACTOR
VONVENDI TM [von Willebrand factor (Recombinant)] IS A PURIFIED RECOMBINANT VON WILLEBRAND FACTOR
WITH AN OPTION TO DOSE INDEPENDENTLY OF RECOMBINANT FACTOR VIII ACCORDING TO PATIENT NEED. 1
For each bleeding episode, administer the first dose of VONVENDI with an approved recombinant (non-von Willebrand factor-containing)
factor VIII (rFVIII) if factor VIII baseline levels are <40% or are unknown. VONVENDI can be administered without rFVIII in some patients if
FVIII levels are ≥40% normal activity (0.4 IU/mL), if an urgent increase is not needed or if the baseline FVIII:C level is sufficient to ensure
hemostasis. 1 Comprehensive dosing information can be found in the VONVENDI full Prescribing Information.
VONVENDI TM [von Willebrand factor (Recombinant)] Important Information
INDICATION Neutralizing Antibodies
VONVENDI TM [von Willebrand factor (Recombinant)] is a recombinant
von Willebrand factor indicated for on-demand treatment and control
of bleeding episodes in adults (age 18 and older) diagnosed with
von Willebrand disease. Neutralizing antibodies (inhibitors) to von Willebrand factor and/
or factor VIII can occur. If the expected plasma levels of VWF
activity (VWF:RCo) are not attained, perform an appropriate assay to
determine if anti-VWF or anti-FVIII inhibitors are present. Consider
other therapeutic options and direct the